News
Boehringer Ingelheim has announced that Praxbind, a reversal agent for the oral anticoagulant Pradaxa (dabigatran etexilate mesylate), is now available in over 2,200 hospitals across the U.S
News
The study analyzed data from NVAF patients newly initiating treatment with dabigatran, rivaroxaban or apixaban.
News
Rivaroxaban, a non-vitamin K antagonist (VKA) oral anticoagulant, was found to have better persistence and lower discontinuation rates than, the VKA warfarin and the non-VKA, dabigatran.
News
Forty-eight percent of atrial fibrillation (AF) patients, who are at the highest risk of stroke, were not prescribed oral anticoagulant (OAC) medication.
